Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;52(4):486-90.
doi: 10.1002/pbc.21883.

Newborn screening for hemoglobinopathies in California

Jennifer Michlitsch  1 , Mahin Azimi, Carolyn Hoppe, Mark C Walters, Bertram Lubin, Fred Lorey, Elliott Vichinsky
Affiliations

Newborn screening for hemoglobinopathies in California

Jennifer Michlitsch et al. Pediatr Blood Cancer. 2009 Apr.

Abstract

Background: Newborn screening (NBS) for hemoglobinopathies facilitates early identification of affected individuals to ensure the prompt institution of comprehensive medical care for affected newborns in California. When linked to extensive follow-up and education, NBS has been shown to significantly reduce mortality in children with sickle cell disease. Due to changing immigration patterns from Asia and Latin America, the State of California has witnessed an increased prevalence of clinically significant hemoglobin (Hb) disorders, including those resulting from novel genotypes. In 1999, newborn screening for Hb H disorders was incorporated in the statewide hemoglobinopathy screening program.

Procedure: Primary screening for hemoglobin variants was performed using high performance liquid chromatography. Confirmatory testing on hemoglobinopathy mutations was performed by electropheresis techniques and genotyping methods.

Results: Of 530,000 newborn samples screened annually in California, 2,118 samples were referred to the Hemoglobin Reference Laboratory (HRL) for confirmatory testing between January 1, 1998 and June 30, 2006 (0.05%). Sickle cell disease was most frequently observed (1 in 6,600 births) followed by alpha-thalassemia (1 in 9,000 births) and beta-thalassemia disease (1 in 55,000 births). The confirmatory analysis modified the initial screening in 5% of cases and revealed 25 rare or new genotypes. Diverse ethnicities were associated with hemoglobin mutations including Southeast Asian, Black, Indian/Asian, Middle Eastern, and Hispanic.

Conclusions: The California hemoglobinopathy screening program provides accurate diagnosis of hemoglobinopathies. Increasing incidence of diverse mutations require new strategies of laboratory screening, counseling, and patient management.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Final diagnoses of all samples forwarded to the HRL from January 1, 1998 through June 30, 2006.
Fig. 2
Fig. 2
Ethnicities of newborns screened in California during this 8-year period.
Fig. 3
Fig. 3
Ethnicities of newborns in California found to have hemoglobin mutations.
See this image and copyright information in PMC

References

    1. Vichinsky E, Hurst D, Earles A, et al. Newborn screening for sickle cell disease: Effect on mortality. Pediatrics. 1988;81:749–755. - PubMed
    1. Rogers DW, Clarke JM, Cupidore L, et al. Early deaths in Jamaican children with sickle cell disease. Br Med J. 1978;1:1515–1516. - PMC - PubMed
    1. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A. randomized trial. N Engl J Med. 1986;314:1593–1599. - PubMed
    1. Vichinsky EP, MacKlin EA, Waye JS, et al. Changes in the epidemiology of thalassemia in North America: A new minority disease. Pediatrics. 2005;116:e818–e825. - PubMed
    1. Chen FE, Ooi C, Ha SY, et al. Genetic and clinical features of hemoglobin H disease in Chinese patients. N Engl J Med. 2000;343:544–550. - PubMed

Publication types